Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company's formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Specialty & Advanced Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:NOVN
- CUSIP: N/A
- Web: www.novantherapeutics.com
- Market Cap: $86.24 million
- Outstanding Shares: 15,984,000
- 50 Day Moving Avg: $6.31
- 200 Day Moving Avg: $6.31
- 52 Week Range: $3.52 - $30.90
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.22
- P/E Growth: 0.00
- Annual Revenue: $768,999.00
- Price / Sales: 109.12
- Book Value: $0.74 per share
- Price / Book: 7.09
- EBIDTA: ($49,040,000.00)
- Return on Equity: -194.61%
- Return on Assets: -99.61%
- Current Ratio: 1.97%
- Quick Ratio: 1.97%
- Average Volume: 117,057 shs.
- Short Ratio: 1.71
Frequently Asked Questions for NOVAN INC (NASDAQ:NOVN)
What is NOVAN INC's stock symbol?
NOVAN INC trades on the NASDAQ under the ticker symbol "NOVN."
How were NOVAN INC's earnings last quarter?
NOVAN INC (NASDAQ:NOVN) announced its quarterly earnings data on Friday, May, 12th. The company reported ($0.73) EPS for the quarter, missing the Zacks' consensus estimate of ($0.49) by $0.24. The business earned $0.10 million during the quarter, compared to the consensus estimate of $10.80 million. View NOVAN INC's Earnings History.
When will NOVAN INC make its next earnings announcement?
Where is NOVAN INC's stock going? Where will NOVAN INC's stock price be in 2017?
4 analysts have issued 1-year target prices for NOVAN INC's shares. Their forecasts range from $6.00 to $31.00. On average, they anticipate NOVAN INC's stock price to reach $16.74 in the next twelve months. View Analyst Ratings for NOVAN INC.
Who are some of NOVAN INC's key competitors?
Some companies that are related to NOVAN INC include OncoMed Pharmaceuticals (OMED), Fate Therapeutics (FATE), Verona Pharma PLC American Depositary Share (VRNA), Viralytics (VRACY), Majesco Entertainment Company (COOL), Vascular Biogenics (VBLT), OBALON THERPTCS (OBLN), Cempra (CEMP), Adamis Pharmaceuticals Corporation (ADMP), Vericel Corporation (VCEL), Recro Pharma (REPH), Conatus Pharmaceuticals (CNAT), Cogentix Medical (CGNT), ConforMIS (CFMS), Summit Therapeutics PLC (SMMT), VBI Vaccines (VBIV), ProQR Therapeutics N.V. (PRQR) and BioDelivery Sciences International (BDSI).
Who are NOVAN INC's key executives?
NOVAN INC's management team includes the folowing people:
- Robert A. Ingram, Independent Chairman of the Board
- Nathan Stasko Ph.D., President, Chief Scientific Officer, Director
- G. Kelly Martin, Interim Chief Executive Officer, Director
- William L. Hodges CPA, Interim Chief Financial Officer, Princiapl Financial Officer, Principal Accounting Officer
- Stanley Hollenbach J.D., Senior Vice President - Research and Development
- Jeff N. Hunter, Vice President - Technical Operations
- Paula Brown Stafford, Chief Development Officer, Director
- Brian M Johnson, Chief Commercial Officer
- W. Kent Geer, Independent Director
- Robert J. Keegan, Independent Director
When did NOVAN INC IPO?
(NOVN) raised $46 million in an initial public offering (IPO) on Wednesday, September 21st 2016. The company issued 3,800,000 shares at $11.00-$13.00 per share. Piper Jaffray served as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who owns NOVAN INC stock?
NOVAN INC's stock is owned by many different of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (1.99%), Vanguard Group Inc. (1.22%), Prospera Financial Services Inc (0.17%) and Goldman Sachs Group Inc. (0.16%). Company insiders that own NOVAN INC stock include John W Palmour, Life Sciences Holdings L Malin and Robert Alexander Ingram. View Institutional Ownership Trends for NOVAN INC.
Who sold NOVAN INC stock? Who is selling NOVAN INC stock?
Who bought NOVAN INC stock? Who is buying NOVAN INC stock?
NOVAN INC's stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc. and Vanguard Group Inc.. Company insiders that have bought NOVAN INC stock in the last two years include John W Palmour, Life Sciences Holdings L Malin and Robert Alexander Ingram. View Insider Buying and Selling for NOVAN INC.
How do I buy NOVAN INC stock?
Shares of NOVAN INC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NOVAN INC's stock price today?
MarketBeat Community Rating for NOVAN INC (NASDAQ NOVN)MarketBeat's community ratings are surveys of what our community members think about NOVAN INC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of NOVAN INC stock can currently be purchased for approximately $5.25.
Consensus Ratings for NOVAN INC (NASDAQ:NOVN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 3 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.75)|
|Consensus Price Target: ||$16.74 (218.90% upside)|
Analysts' Ratings History for NOVAN INC (NASDAQ:NOVN)
(Data available from 9/26/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/3/2017||Piper Jaffray Companies||Reiterated Rating||Buy||Low|
|10/17/2016||Credit Suisse Group||Initiated Coverage||Outperform||$27.00 -> $18.97||N/A|
|10/17/2016||JMP Securities||Initiated Coverage||Outperform||$31.00||N/A|
Earnings History for NOVAN INC (NASDAQ:NOVN)Earnings History by Quarter for NOVAN INC (NASDAQ NOVN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/13/2017|| || || || || || || || |
|5/12/2017||Q1 2017||($0.49)||($0.73)||$10.80 million||$0.10 million||View||N/A|
Earnings Estimates for NOVAN INC (NASDAQ:NOVN)
2017 EPS Consensus Estimate: ($1.47)
2018 EPS Consensus Estimate: ($1.26)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for NOVAN INC (NASDAQ:NOVN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for NOVAN INC (NASDAQ:NOVN)
Insider Ownership Percentage: 10.72%Insider Trades by Quarter for NOVAN INC (NASDAQ:NOVN)
Institutional Ownership Percentage: 6.05%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/29/2017||Robert Alexander Ingram||Director||Buy||12,000||$4.57||$54,840.00|| |
|8/23/2017||John W Palmour||Director||Buy||12,000||$3.99||$47,880.00|| |
|9/26/2016||Life Sciences Holdings L Malin||Major Shareholder||Buy||800,000||$11.00||$8,800,000.00|| |
Headline Trends for NOVAN INC (NASDAQ:NOVN)
Latest Headlines for NOVAN INC (NASDAQ:NOVN)
NOVAN INC (NOVN) Chart for Tuesday, September, 26, 2017